Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 39

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

p53 amyloid aggregation in cancer: function, mechanism, and therapy

Li, Jingzhi, Guo, Ming, Chen, Lin, Chen, Zhuchu, Fu, Ying, Chen, Yongheng · 2022 · Experimental Hematology & Oncology

Abstract

Similar to neurodegenerative diseases, the concept that tumors are prion like diseases has been proposed in recent years. p53, the most well-known tumor suppressor, has been extensively studied for its expression, mutation, and function in various tumors. Currently, an interesting phenomenon of p53 prion-like aggregation has been found in several tumors, and studies have found that its pathological aggregation may lead to functional alterations and ultimately affect tumor progression. It has been demonstrated that the mechanism of p53 aggregation involves its mutation, domains, isoform, etc. In addition to p53 itself, some other factors, including Zn 2+ concentration, pH, temperature and chaperone abnormalities, can also contribute to p53 aggregation. Although there are some studies about the mechanism and role of p53 aggregation and amyloidosis in tumors, there still exist some controversies. In this paper, we review the mechanism of p53 amyloid fibril structure and discuss the characteristics and effects of p53 amyloid aggregation, as well as the pathogenic mechanism leading to the occurrence of aggregation in tumors. Finally, we summarize the various inhibitors targeting p53 aggregation and prion-like behavior. In conclusion, a comprehensive understanding of p53 aggregation can expand our understanding of the causes leading its loss of physiological function and that targeting p53 aggregation might be a promising therapeutic strategy for tumor therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40164-022-00317-7

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 112

  1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–44. · DOI · Paper page
  2. Soto C. Transmissible proteins: expanding the prion heresy. Cell. 2012;149(5):968–77. · DOI · Paper page
  3. Prusiner SB. Cell biology a unifying role for prions in neurodegenerative diseases. Science. 2012;336(6088):1511–3. · DOI · Paper page
  4. Marciniuk K, Taschuk R, Napper S. Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol. 2013;2013: 473706. · DOI
  5. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron. 2009;64(6):783–90. · DOI · Paper page
  6. Navalkar A, Pandey S, Singh N, Patel K, Datta D, Mohanty B, et al. Direct evidence of cellular transformation by prion-like p53 amyloid infection. J Cell Sci. 2021;134(11):jcs258316. · DOI
  7. Palumbo E, Zhao B, Xue B, Uversky VN, Dave V. Analyzing aggregation propensities of clinically relevant PTEN mutants: a new culprit in pathogenesis of cancer and other PTENopathies. J Biomol Struct Dyn. 2020;38(8):2253–66. · DOI
  8. Ghosh S, Salot S, Sengupta S, Navalkar A, Ghosh D, Jacob R, et al. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis. Cell Death Differ. 2017;24(10):1784–98. · DOI
  9. Silva JL, Vieira TC, Gomes MP, Bom AP, Lima LM, Freitas MS, et al. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res. 2010;43(2):271–9. · DOI
  10. Silva JL, De Moura Gallo CV, Costa DC, Rangel LP. Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci. 2014;39(6):260–7. · DOI · Paper page
  11. Silva, JL., Rangel, LP., Costa, DC., Cordeiro, Y. & Moura Gallo, CV. & De, Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep. 2013;33(4):e00054. · DOI
  12. Costa DC, de Oliveira GA, Cino EA, Soares IN, Rangel LP, Silva JL. Aggregation and prion-like properties of misfolded tumor suppressors: is cancer a prion disease? Cold Spring Harb Perspect Biol. 2016;8(10):a023614. · DOI
  13. Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, Braga CA, et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem. 2012;287(33):28152–62. · DOI · Paper page
  14. de Oliveira GAP, Petronilho EC, Pedrote MM, Marques MA, Vieira T, Cino EA, et al. The status of p53 oligomeric and aggregation states in cancer. Biomolecules. 2020;10(4):548. · DOI · Paper page
  15. Lasagna-Reeves CA, Clos AL, Castillo-Carranza D, Sengupta U, Guerrero-Munoz M, Kelly B, et al. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem Biophys Res Commun. 2013;430(3):963–8. · DOI
  16. Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci USA. 1996;93(26):15190–4. · DOI
  17. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol. 1996;16(3):1126–37. · DOI · Paper page
  18. Levy CB, Stumbo AC, Ano Bom AP, Portari EA, Cordeiro Y, Silva JL, et al. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol. 2011;43(1):60–4. · DOI · Paper page
  19. De Smet F, Saiz Rubio M, Hompes D, Naus E, De Baets G, Langenberg T, et al. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. J Pathol. 2017;242(1):24–38. · DOI
  20. Chemes LB, Noval MG, Sanchez IE, de Prat-Gay G. Folding of a cyclin box: linking multitarget binding to marginal stability, oligomerization, and aggregation of the retinoblastoma tumor suppressor AB pocket domain. J Biol Chem. 2013;288(26):18923–38. · DOI
  21. Pedrote MM, Motta MF, Ferretti GDS, Norberto DR, Spohr T, Lima FRS, et al. Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers. iScience. 2020;23(2):100820. · DOI
  22. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011;7(5):285–95. · DOI · Paper page
  23. Navalkar A, Paul A, Sakunthala A, Pandey S, Dey AK, Saha S, et al. Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation. J Cell Sci. 2022;135(15):jcs259500. · DOI
  24. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999;18(6):1660–72. · DOI · Paper page
  25. Gaglia G, Guan Y, Shah JV, Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci USA. 2013;110(38):15497–501. · DOI
  26. Wilcken R, Wang GZ, Boeckler FM, Fersht AR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. P Natl Acad Sci USA. 2012;109(34):13584–9. · DOI · Paper page
  27. Silva JL, Cino EA, Soares IN, Ferreira VF, de Oliveira AP, G. Targeting the prion-like aggregation of mutant p53 to combat cancer. Acc Chem Res. 2018;51(1):181–90. · DOI
  28. Rangel LP, Costa DC, Vieira TC, Silva JL. The aggregation of mutant p53 produces prion-like properties in cancer. Prion. 2014;8(1):75–84. · DOI
  29. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol. 2004;15(1):3–16. · DOI · Paper page
  30. Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol. 2018;19(12):755–73. · DOI · Paper page
  31. Romero D, Aguilar C, Losick R, Kolter R. Amyloid fibers provide structural integrity to Bacillus subtilis biofilms. Proc Natl Acad Sci USA. 2010;107(5):2230–4. · DOI · Paper page
  32. Lipke PN, Klotz SA, Dufrene YF, Jackson DN, Garcia-Sherman MC. Amyloid-like beta-aggregates as force-sensitive switches in fungal biofilms and infections. Microbiol Mol Biol Rev. 2017;82(1):e00035–17. · DOI
  33. Garvey M, Ecroyd H, Ray NJ, Gerrard JA, Carver JA. Functional amyloid protection in the eye lens: retention of alpha-crystallin molecular chaperone activity after modification into amyloid fibrils. Biomolecules. 2017;7(3):67. · doi:10.3390/biom7030067
  34. Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol. 1999;309:256–74. · DOI · Paper page
  35. Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66(2 Suppl 1):S74–8. · DOI · Paper page
  36. Meisl G, Kirkegaard JB, Arosio P, Michaels TC, Vendruscolo M, Dobson CM, et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat Protoc. 2016;11(2):252–72. · DOI · Paper page
  37. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86. · DOI · Paper page
  38. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8. · DOI · Paper page
  39. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255(5043):459–62. · DOI · Paper page
  40. Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS ONE. 2012;7(12): e51426. · DOI · Paper page
  41. Kirilyuk A, Shimoji M, Catania J, Sahu G, Pattabiraman N, Giordano A, et al. An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation. PLoS ONE. 2012;7(11): e48243. · DOI
  42. Mello SS, Attardi LD. Not all p53 gain-of-function mutants are created equal. Cell Death Differ. 2013;20(7):855–7. · DOI
  43. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991;65(5):765–74. · DOI · Paper page
  44. Ishimaru D, Andrade LR, Teixeira LS, Quesado PA, Maiolino LM, Lopez PM, et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry. 2003;42(30):9022–7. · DOI · Paper page
  45. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672–88. · DOI · Paper page
  46. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect a monoclonal antibody specific for the mutant form. EMBO J. 1990;9(5):1595–602. · DOI · Paper page
  47. Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A, et al. The (1–63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J. 2008;94(9):3635–46. · DOI
  48. Das A, Makarov DE. Effect of mutation on an aggregation-prone segment of p53: from monomer to dimer to multimer. J Phys Chem B. 2016;120(45):11665–73. · DOI
  49. Ghosh S, Ghosh D, Ranganathan S, Anoop A, Jha NN, Padinhateeri R, Maji SK, et al. Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53. Biochemistry. 2014;53(38):5995–6010. · DOI
  50. Butler JS, Loh SN. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry. 2003;42(8):2396–403. · DOI · Paper page
  51. Forget KJ, Tremblay G, Roucou X. p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53. PLoS ONE. 2013;8(7): e69242. · DOI
  52. Higashimoto Y, Asanomi Y, Takakusagi S, Lewis MS, Uosaki K, Durell SR, et al. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry. 2006;45(6):1608–19. · DOI · Paper page
  53. Lee AS, Galea C, DiGiammarino EL, Jun B, Murti G, Ribeiro RC, et al. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant. J Mol Biol. 2003;327(3):699–709. · DOI
  54. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 1999;18(53):7621–36. · DOI · Paper page
  55. Wang G, Fersht AR. Multisite aggregation of p53 and implications for drug rescue. Proc Natl Acad Sci USA. 2017;114(13):E2634–43. · DOI · Paper page
  56. Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden KH. Functional interplay between MDM2, p63/p73 and mutant p53. Oncogene. 2015;34(33):4300–10. · DOI
  57. Khoury MP, Bourdon JC. p53 Isoforms: an intracellular microprocessor? Genes Cancer. 2011;2(4):453–65. · DOI · Paper page
  58. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, et al. Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene. 2002;21(44):6722–8. · DOI · Paper page
  59. Khoury MP, Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol. 2010;2(3): a000927. · DOI · Paper page
  60. Fujita K. p53 isoforms in cellular senescence- and ageing-associated biological and physiological functions. Int J Mol Sci. 2019;20(23):6023. · DOI
  61. Vieler M, Sanyal S. p53 isoforms and their implications in cancer. Cancers (Basel). 2018;10(9):288. · DOI
  62. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817–25. · DOI · Paper page
  63. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9(6):1799–805.
  64. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992;12(6):2866–71.
  65. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, et al. Further characterisation of the p53 responsive element–identification of new candidate genes for trans-activation by p53. Oncogene. 1997;14(1):85–94. · DOI
  66. Kim S, An SS. Role of p53 isoforms and aggregations in cancer. Medicine (Baltimore). 2016;95(26): e3993. · DOI
  67. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res. 2006;12(13):3985–92. · DOI
  68. Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, et al. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2015;34(27):3605–16. · DOI
  69. Melo Dos Santos N, de Oliveira GAP, Ramos Rocha M, Pedrote MM, da Silva D, Ferretti G, Pereira Rangel L, et al. Loss of the p53 transactivation domain results in high amyloid aggregation of the Delta40p53 isoform in endometrial carcinoma cells. J Biol Chem. 2019;294(24):9430–9. · DOI
  70. Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 2009;583(16):2685–90. · DOI
  71. Chen CD, Huff ME, Matteson J, Page L, Phillips R, Kelly JW, et al. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J. 2001;20(22):6277–87. · DOI
  72. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. 2003;17(6):909–27. · DOI
  73. Cordeiro Y, Vieira T, Kovachev PS, Sanyal S, Silva JL. Modulation of p53 and prion protein aggregation by RNA. Biochim Biophys Acta Proteins Proteom. 2019;1867(10):933–40. · DOI
  74. Surguchev A, Surguchov A. Conformational diseases: Looking into the eyes. Brain Res Bull. 2010;81(1):12–24. · DOI
  75. Fraser PE, Nguyen JT, Inouye H, Surewicz WK, Selkoe DJ, Podlisny MB, et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry. 1992;31(44):10716–23. · DOI · Paper page
  76. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science. 1997;13(22):15.
  77. Guzzo A, Delarue P, Rojas A, Nicolai A, Maisuradze GG, Senet P. Missense mutations modify the conformational ensemble of the alpha-synuclein monomer which exhibits a two-phase characteristic. Front Mol Biosci. 2021;8: 786123. · DOI
  78. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466–74. · DOI · Paper page
  79. Hinault MP, Ben-Zvi A, Goloubinoff P. Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging. J Mol Neurosci. 2006;30(3):249–65. · DOI
  80. Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol. 2013;14(10):630–42. · DOI · Paper page
  81. Wang X, Wang F, Sy MS, Ma J. Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol. J Biol Chem. 2005;280(1):317–25. · DOI
  82. Hishiya A, Takayama S. Molecular chaperones as regulators of cell death. Oncogene. 2008;27(50):6489–506. · DOI
  83. Lopez de la Paz M, Serrano L. Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci USA. 2004;101(1):87–92. · DOI · Paper page
  84. Meinhardt J, Tartaglia GG, Pawar A, Christopeit T, Hortschansky P, Schroeckh V, et al. Similarities in the thermodynamics and kinetics of aggregation of disease-related Abeta(1–40) peptides. Protein Sci. 2007;16(6):1214–22. · DOI
  85. DuBay KF, Pawar AP, Chiti F, Zurdo J, Dobson CM, Vendruscolo M. Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J Mol Biol. 2004;341(5):1317–26. · DOI · Paper page
  86. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A. The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates. Protein Sci. 2004;13(7):1939–41. · DOI · Paper page
  87. Christopeit T, Hortschansky P, Schroeckh V, Guhrs K, Zandomeneghi G, Fandrich M. Mutagenic analysis of the nucleation propensity of oxidized Alzheimer’s beta-amyloid peptide. Protein Sci. 2005;14(8):2125–31. · DOI
  88. Almeida ZL, Brito RMM. Structure and aggregation mechanisms in amyloids. Molecules. 2020;25(5):1195. · DOI · Paper page
  89. Kovachev PS, Banerjee D, Rangel LP, Eriksson J, Pedrote MM, Martins-Dinis M, et al. Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain. J Biol Chem. 2017;292(22):9345–57. · DOI
  90. Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Yoshida T, Itoh H, et al. Binding of RNA to p53 regulates its oligomerization and DNA-binding activity. Oncogene. 2004;23(25):4371–9. · DOI
  91. Toretsky JA, Wright PE. Assemblages: functional units formed by cellular phase separation. J Cell Biol. 2014;206(5):579–88. · DOI · Paper page
  92. Selivanova G. Wild type p53 reactivation: from lab bench to clinic. FEBS Lett. 2014;588(16):2628–38. · DOI
  93. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010;2(9): a001222. · DOI · Paper page
  94. Friedler A, Veprintsev DB, Hansson LO, Fersht AR. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem. 2003;278(26):24108–12. · DOI · Paper page
  95. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 1999;286(5449):2507–10. · DOI · Paper page
  96. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest. 2007;117(12):3753–64. · DOI · Paper page
  97. Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 2014;588(16):2622–7. · DOI · Paper page
  98. Rangel LP, Ferretti GDS, Costa CL, Andrade S, Carvalho RS, Costa DCF, et al. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells. J Biol Chem. 2019;294(10):3670–82. · DOI
  99. Miller JJ, Blanchet A, Orvain C, Nouchikian L, Reviriot Y, Clarke RM, et al. Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chem Sci. 2019;10(46):10802–14. · DOI · Paper page
  100. Palanikumar L, Karpauskaite L, Al-Sayegh M, Chehade I, Alam M, Hassan S, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12(1):3962. · DOI · Paper page
  101. Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375–404. · DOI · Paper page
  102. Wang G, Fersht AR. First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci USA. 2012;109(34):13590–5. · DOI · Paper page
  103. Kumar S, Henning-Knechtel A, Magzoub M, Hamilton AD. Peptidomimetic-based multidomain targeting offers critical evaluation of abeta structure and toxic function. J Am Chem Soc. 2018;140(21):6562–74. · DOI
  104. Kumar S, Hamilton AD. alpha-Helix mimetics as modulators of a beta self-assembly. J Am Chem Soc. 2017;139(16):5744–55. · DOI
  105. Kulikov OV, Kumar S, Magzoub M, Knipe PC, Saraogi I, Thompson S, et al. Amphiphilic oligoamide alpha-helix peptidomimetics inhibit islet amyloid polypeptide aggregation. Tetrahedron Lett. 2015;56(23):3670–3. · DOI
  106. Kumar S, Schlamadinger DE, Brown MA, Dunn JM, Mercado B, Hebda JA, et al. Islet amyloid-induced cell death and bilayer integrity loss share a molecular origin targetable with oligopyridylamide-based alpha-helical mimetics. Chem Biol. 2015;22(3):369–78. · DOI
  107. Bom AP, Freitas MS, Moreira FS, Ferraz D, Sanches D, Gomes AM, et al. The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure. J Biol Chem. 2010;285(4):2857–66. · DOI
  108. De Simone A, Dodson GG, Verma CS, Zagari A, Fraternali F. Prion and water: tight and dynamical hydration sites have a key role in structural stability. Proc Natl Acad Sci USA. 2005;102(21):7535–40. · DOI
  109. Accordino SR, Rodriguez Fris JA, Appignanesi GA. Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53. PLoS ONE. 2013;8(1): e55123. · doi:10.1371/journal.pone.0055123
  110. Vogler TO, Wheeler JR, Nguyen ED, Hughes MP, Britson KA, Lester E, et al. TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature. 2018;563(7732):508–13. · DOI · Paper page
  111. Malaney P, Uversky VN, Dave V. PTEN proteoforms in biology and disease. Cell Mol Life Sci. 2017;74(15):2783–94. · DOI
  112. Claes F, Maritschnegg E, De Baets G, Siekierska A, Rubio MS, Ramakers M, et al. The tumor suppressor protein PTEN undergoes amyloid-like aggregation in tumor cells. bioRxiv. 2020;11(30):402115.

Cited by

See all 39

Metadata

Authors
Li, J., Guo, M., Chen, L., Chen, Z., Fu, Y., & Chen, Y.
Venue
Experimental Hematology & Oncology
Published
2022-09-28
Volume
11
Issue
1
ISSN
2162-3619
Cited by
39
References
12
Language
en
Licence
Funders
  • National Natural Science Foundation of China (81502542, 81570537, 81974074 and 82172654)
  • Hunan Provincial Science and Technology Department (2018RS3026 and 2021RC4012)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: p53 amyloid aggregation in cancer: function, mechanism, and therapy. https://app.cochat.ai/papers/10.1186/s40164-022-00317-7
The paper
Li, J., Guo, M., Chen, L., Chen, Z., Fu, Y., & Chen, Y. (2022). p53 amyloid aggregation in cancer: function, mechanism, and therapy. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-022-00317-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.